Objective: Case reports and small patient series have suggested peripheral nerve field stimulation (PNFS) as a treatment for refractory trigeminal neuralgia attributed to multiple sclerosis (MS). Here, the authors aimed to assess the effects of this technique on long-term pain severity.
Methods: Data were prospectively collected on patients with refractory trigeminal neuralgia attributed to MS who underwent PNFS between July 2013 and August 2017 at the authors' neurosurgical department. Patients were evaluated before and after the first treatment as well as at follow-up at least twice a year. Patients underwent assessment of their pain severity using the Barrow Neurological Institute (BNI) Scale before treatment and at follow-up and were questioned about adverse events following cranial MRI performed after implantation of a permanent PNFS system.
Results: Eight patients (3 women) underwent PNFS trials and their median age was 61 years (IQR 73.75 - 46.5 years). Seven patients proceeded to permanent implantation of the stimulation system. At a median follow-up of 33 months (IQR 42 - 24 months), pain severity decreased from baseline to the last follow-up (BNI score decrease from V [IQR V - V] to III [IQR V - III], p = 0.054). Four patients experienced long-lasting benefit (at 48, 33, 24, and 15 months' follow-up, respectively), while in 3 patients the treatment eventually failed after an initially successful period. One patient had an infection, requiring system removal and subsequent reimplantation. No other complications occurred. No adverse events were noted in the patients undergoing MRI postimplantation.
Conclusions: This analysis indicates a possibly beneficial long-term effect of PNFS on refractory trigeminal neuralgia attributed to MS in some patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3171/2019.12.JNS192261 | DOI Listing |
Curr Pain Headache Rep
January 2025
Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Purpose Of Review: This review discusses the diagnosis and treatment of nervus intermedius neuralgia (NIN) and identifies gaps in the literature.
Recent Findings: The nervus intermedius is a branch of the facial nerve. NIN presents as a rare neuralgia of this nerve, causing deep ear pain, which may radiate to the auditory canal, auricle, mastoid, soft palate, temple, and angle of the jaw.
J Oral Facial Pain Headache
March 2024
Faculty of Dentistry, Oral & Craniofacial Science, King's College London, SE5 8AF London, UK.
This case series aimed to assess the treatment outcomes of onabotulinum toxin A (BTX-A) in patients with refractory posttraumatic trigeminal neuropathic pain (PTNP) and to conduct a narrative review of the evidence for BTX-A in PTNP. Thirteen patients were treated with BTX-A infiltrations. Patient demographic and pain characteristics, BTX-A administration, and treatment outcomes were retrospectively analyzed.
View Article and Find Full Text PDFJ Neurosurg Case Lessons
December 2024
Division of Neurosurgery, Children's Hospital Los Angeles, Los Angeles, California.
Background: Glossopharyngeal neuralgia (GPN) is a rare condition typically manifesting as paroxysms of sharp, lancinating pain localized to the middle ear and auditory canal, base of the tongue, tonsillar fossa, and region just inferior to the angle of the mandible. Vascular compression is a common etiology, and microvascular decompression (MVD) has been established as a safe and efficacious treatment in adults. With the exception of one report of an adult patient undergoing the procedure for symptomatology that began in adolescence, there are no published cases of MVD for GPN in pediatric patients to the author's knowledge.
View Article and Find Full Text PDFCurr Neurol Neurosci Rep
December 2024
Department of Neurology, Headache Division, Mayo Clinic, Rochester, MN, USA.
Purpose Of Review: Discuss the current understanding of the pathophysiology and management of refractory trigeminal neuralgia (TN). This includes a discussion on why TN can recur after microvascular decompression and a discussion on "outside of the box" options when both first- and second-line management strategies have been exhausted.
Recent Findings: This review discusses second- and third-line oral medication options, botulinum toxin A, repeat microvascular decompression, repeat ablative procedures, internal neurolysis, trigeminal branch blockade, and neuromodulation using TMS or peripheral stimulation.
Cureus
November 2024
Unidade de Neurofisiologia Clínica, Centro Hospitalar Universitário de Lisboa Central, Lisboa, PRT.
Trigeminal neuralgia (TN) stands as a common neuropathic pain disorder. Clinically, it manifests with episodes characterized by unilateral electric shock-like or knife-like pain that can involve one or more divisions of the fifth cranial nerve. Botulinum neurotoxin type A (BoNT-A) is a neurotoxin that has demonstrated analgesic effects in neuropathic pain and positive benefits in the treatment of refractory idiopathic TN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!